On June 13, 2024, eFFECTOR Therapeutics, Inc. conducted its 2024 Annual Meeting of Stockholders, during which several key decisions were made. The stockholders approved an amendment to increase the authorized number of shares of common stock from 40 million to 80 million. This amendment was made effective with the filing of a Certificate of Amendment on June 14, 2024. Additionally, two Class III directors, Elizabeth P. Bhatt and Barbara Klencke, M.D., were elected to serve a three-year term. The company also ratified the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024. The approval of these items was confirmed by the number of votes cast for and against each matter, with the amendment to increase authorized shares receiving 1,972,682 votes for, 678,077 against, and 23,782 abstentions.

On June 13, 2024, eFFECTOR Therapeutics, Inc. conducted its 2024 Annual Meeting of Stockholders, during which several key decisions were made. The stockholders approved an amendment to increase the authorized number of shares of common stock from 40 million to 80 million. This amendment was made effective with the filing of a Certificate of Amendment on June 14, 2024. Additionally, two Class III directors, Elizabeth P. Bhatt and Barbara Klencke, M.D., were elected to serve a three-year term. The company also ratified the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024. The approval of these items was confirmed by the number of votes cast for and against each matter, with the amendment to increase authorized shares receiving 1,972,682 votes for, 678,077 against, and 23,782 abstentions.